Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies Meeting Abstract
| Authors: | DiNardo, C. D.; Savona, M. R.; Kishtagari, A.; Fathi, A. T.; Bhalla, K. N.; Agresta, S.; Reilly, S.; Almon, C.; Hentemann, M.; Hickman, D.; Corrigan, D.; Macaraeg, M.; Piel, J.; Horrigan, K.; Nabhan, S.; Martin, P.; Stein, E. M. |
| Abstract Title: | Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4284 |
| Language: | English |
| ACCESSION: | WOS:001159740307030 |
| DOI: | 10.1182/blood-2023-178090 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
